Does Wegovy stop working after a while — and what can you do about it?

Step 1, Understand the pattern: what the clinical trials actually show

The STEP 1 trial, published in the New England Journal of Medicine, tracked adults taking semaglutide 2.4mg weekly over 68 weeks. Average weight loss was around 15% of body weight. Crucially, that loss was not evenly spread across the timeline. The steepest drop happened in the first 20 or so weeks, after which the curve flattened, weight continued to fall, but more slowly, before reaching a rough plateau around weeks 60–68.

This shape is not a sign of failure. It reflects how appetite regulation, energy expenditure, and metabolic adaptation interact once the body reaches a new lower set-point. The medicine is still working during that flatter stretch. You can read more about when Wegovy starts working in the first place to understand the full arc from the first dose onwards.

What the trials also showed is that people who stopped semaglutide regained most of the lost weight within a year. That finding points to an important truth: the medicine is actively maintaining results even when the number on the scale is barely moving. The job in a plateau phase is not to start again, it is to stay the course with clinical oversight.

Step 2, Diagnose which type of slowdown you are experiencing

Not every plateau is the same, and a prescriber will think through several possibilities before deciding what to do. The main explanations are worth knowing.

First, biological adaptation. As you lose weight, your resting metabolic rate drops, a lighter body simply burns fewer calories at rest. This is not a Wegovy-specific phenomenon; it happens with every meaningful weight-loss intervention. Semaglutide suppresses appetite but cannot fully counteract the downward shift in how much energy a smaller body needs.

Second, calorie creep. Appetite suppression is powerful in the early weeks but can become less dramatic over time, particularly during a dose hold. If portion sizes drift upward without much conscious awareness (something our prescribers hear from patients quite regularly) the calorie balance shifts even while the medicine is doing its job on hunger signalling.

Third, dose titration. Wegovy is titrated gradually from 0.25mg upward to the 2.4mg maintenance dose. Someone still early in that escalation may experience a pause in progress that resolves once the therapeutic dose is reached. There is separate detail on how long semaglutide takes to work as dose increases compound.

Fourth, and less commonly, there may be a physiological reason semaglutide is not responding as expected for a specific individual, factors including other medications, gut absorption and concurrent health conditions all play a role that only a clinical review can unpick.

Step 3, What a prescriber can actually do

A genuine, prolonged stall is something to bring to your prescriber rather than sit with in silence. There are several routes available after a clinical review.

If you have not yet reached the 2.4mg maintenance dose and have been tolerating the current dose well, a titration step may be the most straightforward option. The NHS patient information for semaglutide describes the standard titration schedule; moving through it is always a prescriber's decision based on tolerability and response.

NICE's appraisal of semaglutide for weight management states that if there has been less than 5% weight loss after six months at the maintenance dose, the clinical appropriateness of continuing should be reviewed. That threshold is not a punishment, it is a safety and resource consideration built into good clinical practice, and an honest prescriber will discuss it with you openly.

For some people, the conversation at a review also covers whether switching to a different medicine might be appropriate. Tirzepatide, the active ingredient in Mounjaro, is a dual GIP and GLP-1 receptor agonist; head-to-head evidence from the SURMOUNT-5 trial suggests it typically produces greater average weight loss than semaglutide 2.4mg. Whether a switch is right depends on a full clinical picture, including tolerability history and any other health conditions. You can explore how semaglutide works and the full picture on Wegovy to inform that conversation.

Finally, a review is a good moment to look honestly at lifestyle factors alongside treatment. Protein adequacy, hydration, sleep and resistance activity all influence how the body responds during a plateau. None of that replaces the clinical discussion, but all of it feeds into it.

Step 4, When it really is time to reassess

There are situations where stopping is the right clinical decision. If you have been at the maintenance dose for six months and weight loss remains below 5%, if side effects have made treatment difficult to sustain, or if your health picture has changed, your prescriber should have an open conversation with you about the path forward.

This is worth thinking about alongside the psychological effects of being on Wegovy, some people find that a plateau affects motivation and mood in ways that are worth addressing directly, not just monitoring quietly.

If you are considering the cost of treatment during a period when progress feels slow, the context around Wegovy pricing in the UK is a practical read. A clinical reassessment at that point is free at nume; every repeat order is reviewed by a prescriber before it is dispensed, which means a plateau is naturally part of that conversation.

Weight loss medicine is not a linear journey, and a plateau rarely means the end of the road. Speak to our prescribers if things have stalled, a review takes minutes, and the answer usually points somewhere constructive.